Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Monotherapy in CD20+ Malignancies (GAUGUIN)
NCT00517530Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2007
- Primary completion
- Nov 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of obinutuzumab in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), sponsored by Roche. Started Sep 2007; status: completed.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00517530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00517530.